Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Fate Therapeutics ( (FATE) ).
On October 26, 2025, Fate Therapeutics announced promising results from a Phase 1 clinical trial of its FT819 CAR T-cell therapy for systemic lupus erythematosus (SLE), presented at the ACR Convergence 2025. The trial, involving 10 patients, demonstrated significant reductions in disease activity scores and favorable safety profiles, suggesting potential for outpatient treatment and same-day discharge. The company is also advancing its clinical programs with plans for a pivotal study in 2026, aiming to enhance its market position in autoimmune disease treatment.
The most recent analyst rating on (FATE) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Fate Therapeutics stock, see the FATE Stock Forecast page.
Spark’s Take on FATE Stock
According to Spark, TipRanks’ AI Analyst, FATE is a Neutral.
Fate Therapeutics’ overall stock score is primarily impacted by its financial performance challenges, including persistent losses and negative cash flow. While technical analysis shows bullish momentum, the negative valuation metrics, such as the negative P/E ratio, weigh heavily on the score. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on FATE stock, click here.
More about Fate Therapeutics
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies. The company’s primary market focus is on providing broad accessibility to these therapies for patients, particularly in the treatment of autoimmune diseases and oncology.
Average Trading Volume: 1,986,685
Technical Sentiment Signal: Sell
Current Market Cap: $190.3M
For detailed information about FATE stock, go to TipRanks’ Stock Analysis page.